New drug cocktail aims to supercharge immune attack on prostate cancer before surgery
NCT ID NCT03899987
First seen May 05, 2026 · Last updated Jun 05, 2026 · Updated 5 times
Summary
This study tests whether a combination of three drugs (enteric-coated aspirin, rintatolimod, and interferon-alpha 2b) can boost the immune system's ability to fight prostate cancer before surgery. About 12 men with localized prostate cancer who plan to have their prostate removed will participate. The goal is to see if this treatment increases immune cells in the tumor, potentially reducing the risk of cancer coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.